VMAT2: A dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse

Annals of the New York Academy of Sciences

Volumn 1216, Issue 1, 2011, Pages 86-98

  Eiden, Lee E ^a   Weihe, Eberhard ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Addiction; Amphetamine; Cocaine; Monoamines; Vesicular transporter; VMAT2

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; ADRENALIN; AMPHETAMINE; BRAIN MONOAMINE; COCAINE; DOPAMINE; FENFLURAMINE; HISTAMINE; METHAMPHETAMINE; NORADRENALIN; PHENETHYLAMINE; SEROTONIN; TETRABENAZINE; TYRAMINE; VESICULAR MONOAMINE TRANSPORTER 1; VESICULAR MONOAMINE TRANSPORTER 2;

ALZHEIMER DISEASE; ARTICLE; BIOCHEMISTRY; BRAIN FUNCTION; CATECHOLAMINE NERVE CELL; COCAINE DEPENDENCE; CYTOLOGY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; DRUG ABUSE; DRUG DEPENDENCE; ENZYME SPECIFICITY; EPIGENETICS; GENETICS; GILLES DE LA TOURETTE SYNDROME; HUMAN; HUNTINGTON CHOREA; IMAGING; IMMUNOHISTOCHEMISTRY; MONOAMINE NERVE CELL; NERVE CELL PLASTICITY; NERVE FUNCTION; NEUROANATOMY; NEUROCHEMISTRY; NONHUMAN; NORADRENERGIC NERVE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; REWARD; SCHIZOPHRENIA; SEROTONINERGIC NERVE CELL; STRESS;

EID: 79251565568     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05906.x     Document Type: Article

References (92)

1. Kirshner, N. 1962. Uptake of catecholamines by a particulate fraction of the adrenal medulla. J. Biol. Chem. 237: 2311-2317.
2. Johnson Jr., R.G. 1988. Accumulation of biological amines into chromaffin granules: a model for hormone and neurotransmitter transport. Physiol. Revs. 68: 232-307.
3. Eiden, L.E. 2000. The vesicular neurotransmitter transporters: current perspectives and future prospects. FASEB J. 14: 2396-2400.
4. Eiden, L.E. et al 2004. The vesicular amine transporter family (SLC18): amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine. Pflugers Arch. 447: 636-640.
5. Schuldiner, S., A. Shirvan & M. Linial 1995. Vesicular neurotransmitter transporters: from bacteria to humans. Physiol. Rev. 75: 369-392.
6. Henry, J.-P. et al 1998. The vesicular monoamine transporter: from chromaffin granule to brain. Neurochem. Int. 32: 227-246.
7. Erickson, J.D., L.E. Eiden & B. Hoffman 1992. Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc. Natl. Acad. Sci. USA 89: 10993-10997.
8. Liu, Y. et al 1992. A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter. Cell. 70: 539-551.
9. Erickson, J.D. & L.E. Eiden 1993. Functional identification and molecular cloning of a human brain vesicle monoamine transporter. J. Neurochem. 61: 2314-2317.
10. Peter, D. et al 1995. Differential expression of two vesicular monoamine transporters. J. Neurosci. 15: 6179-6188.
11. Weihe, E. et al 1994. Localization of vesicular monoamine transporter isoforms (VMAT1 and VMAT2) to endocrine cells and neurons in rat. J. Mol. Neurosci. 5: 149-164.
12. Vardy, E. et al 2004. Structural conservation in the major facilitator superfamily as revealed by comparative modeling. Protein Sci. 13: 1832-1840.
13. Kariya, S. et al 2005. Increased vulnerability to L-DOPA toxicity in dopaminergic neurons from VMAT2 heterozygote knockout mice. J. Mol. Neurosci. 27: 277-279.
14. Takahashi, N. et al 1997. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc. Natl. Acad. Sci. USA 94: 9938-9943.
15. Chaudhry, F.A., R.H. Edwards & F. Fonnum 2008. Vesicular neurotransmitter transporters as targets for endogenous and exogenous toxic substances. Annu. Rev. Pharmacol. Toxicol. 48: 277-301.
16. Fon, E.A. et al 1997. Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron 19: 1271-1283.
17. Wang, Y.-M. et al 1997. Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 19: 1285-1296.
18. Lohoff, F.W. et al 2008. Association between polymorphisms in the vesicular monoamine transporter 1 gene (VMAT1/SLC18A1) on chromosome 8p and schizophrenia. Neuropsychobiology 57: 55-60.
19. Lohoff, F.W. et al 2006. Variations in the vesicular monoamine transporter 1 gene (VMAT1/SLC18A1) are associated with bipolar i disorder. Neuropsychopharmacology 31: 2739-2747.
20. Chu, T.T. & Y. Liu 2010. An integrated genomic analysis of gene-function correlation on schizophrenia susceptibility genes. J. Hum. Genet. 55: 285-292.
21. Lin, Z. et al 2005. SLC18A2 promoter haplotypes and identification of a novel protective factor against alcoholism. Hum. Mol. Genet. 14: 1393-1404.
22. Efange, S.M.N. 2000. In vivo imaging of the vesicular acetylcholine transporter and the vesicular monoamine transporter. FASEB J. 14: 2401-2413.
23. Erickson, J.D. & H. Varoqui 2000. Molecular analysis of vesicular amine transporter function and targeting to secretory organelles. FASEB J. 14: 2450-2458.
24. Parsons, S.M. 2000. Transport mechanisms in acetylcholine and monoamine storage. FASEB J. 14: 2423-2434.
25. Rand, J.B., J.S. Duerr & D.L. Frisby 2000. Neurogenetics of vesicular transporters in C. elegans. FASEB J. 14: 2414-2422.
26. Uhl, G.R. et al 2000. The VMAT2 gene in mice and humans: amphetamine responses, locomotion, cardiac arrhythmias, aging, and vulnerability to dopaminergic toxins. FASEB J. 14: 2459-2476.
27. Weihe, E. & L.E. Eiden 2000. Vesicular amine transporter expression in amine-handling cells of the nervous, endocrine and inflammatory systems. FASEB J. 14: 2435-2449.
28. Weihe, E. & L.E. Eiden 2000. Chemical neuroanatomy of the vesicular amine transporters. FASEB J. 14: 2435-2449.
29. Hansson, S.R., B.J. Hoffman & E. Mezey 1998. Ontogeny of vesicular monoamine transporter mRNAs VMAT1 and VMAT2. I. The developing rat central nervous system. Dev. Brain Res. 110: 135-158.
30. Schütz, B. et al 1998. Ontogeny of vesicular amine transporter expression in the rat: new perspectives on aminergic neuronal and neuroendocrine differentiation. Adv. Pharmacol. 42: 903-908.
31. Schütz, B. et al 1998. Vesicular amine transporter expression and isoform selection in developing brain, peripheral nervous system and gut. Dev. Brain Res. 106: 181-204.
32. Erickson, J.D. et al 1996. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc. Natl. Acad. Sci. USA 93: 5166-5171.
33. Lohoff, F.W. 2010. Genetic variants in the vesicular monoamine transporter 1 (VMAT1/SLC18A1) and neuropsychiatric disorders. Methods Mol. Biol. 637: 165-180.
34. Lohoff, F.W. et al 2008. Association between variation in the vesicular monoamine transporter 1 gene on chromosome 8p and anxiety-related personality traits. Neurosci. Lett. 434: 41-45.
35. Borowsky, B. et al 2001. Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc. Natl. Acad. Sci. USA 98: 8966-8971.
36. Weihe, E. et al 2006. Three types of tyrosine hydroxylase-positive CNS neurons distinguished by dopa decarboxylase and VMAT2 co-expression. Cell Mol. Neurobiol. 26: 659-678.
37. Weihe, E. et al 2005. Co-expression of cholinergic and noradrenergic phenotypes in human and non-human autonomic nervous system. J. Comp. Neurol. 492: 370-379.
38. Habecker, B.A. et al 2000. Norepinephrine transporter expression in cholinergic sympathetic neurons: differential regulation of membrane and vesicular transporters. Dev. Biol. 220: 85-96.
39. Chang, L. et al 2007. Structural and metabolic brain changes in the striatum associated with methamphetamine abuse. Addiction. 102(Suppl 1): 16-32.
40. Fleckenstein, A.E. et al 2007. New insights into the mechanism of action of amphetamines. Annu. Rev. Pharmacol. Toxicol. 47: 681-698.
41. Hyman, S.E., R.C. Malenka & E.J. Nestler 2006. Neural mechanisms of addiction: the role of reward-related learning and memory. Annu. Rev. Neurosci. 29: 565-598.
42. Laakso, A. et al 2002. Experimental genetic approaches to addiction. Neuron 36: 213-228.
43. Nestler, E.J. & G.K. Aghajanian 1997. Molecular and cellular basis of addiction. Science 278: 58-63.
44. Lebrand, C. et al 1998. Transient developmental expression of monoamine transporters in the rodent forebrain. J. Comp. Neurol. 401: 506-524.
45. Rokyta, R. et al 2008. Prenatal and perinatal factors influencing nociception, addiction and behavior during ontogenetic development. Physiol. Res. 57(Suppl 3): S79-S88.
46. McClung, C. & J. Hirsh 1999. The trace amine tyramine is essential for sensitization to cocaine in Drosophila. Curr. Biol. 9: 853-860.
47. Boulton, A.A. 1978. The tyramines: functionally significant biogenic amines or metabolic accidents Life Sci. 23: 659-671.
48. Ugrumov, M. et al 2002. Tyrosine hydroxylase- and/or aromatic L-amino acid decarboxylase-expressing neurons in the rat arcuate nucleus: ontogenesis and functional significance. Psychoneuroendocrinology. 27: 533-548.
49. Branicky, R. & W.R. Schafer 2009. Tyramine: a new receptor and a new role at the synapse. Neuron 62: 458-460.
50. Gainetdinov, R.R. & M.G. Caron 2003. Monoamine transporters: from genes to behavior. Annu. Rev. Pharmacol. Toxicol. 43: 261-284.
51. Truong, J.G. et al 2003. Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration. Eur J Pharmacol. 474: 223-226.
52. Dwoskin, L.P. & P.A. Crooks 2002. A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse. Biochem. Pharmacol. 63: 89-98.
53. Duerr, J.S. et al 1999. The cat-1 gene of Caenorhabditis elegans encodes a vesicular monoamine transporter required for specific monoamine-dependent behaviors. J. Neurosci. 19: 72-84.
54. De Gois, S. et al 2005. Homeostatic scaling of vesicular glutamate and GABA transporter expression in rat neocortical circuits. J. Neurosci. 25: 7121-7133.
55. Song, H. et al 1997. Expression of a putative vesicular acetylcholine transporter facilitates quantal transmitter packaging. Neuron 18: 815-826.
56. Schutz, B., E. Weihe & L. E. Eiden 2001. Independent patterns of transcription for the products of the rat cholinergic gene locus. Neuroscience 104: 633-642.
57. Ozkan, E.D., F.S. Lee & T. Ueda 1997. A protein factor that inhibits ATP-dependent glutamate and gamma-aminobutyric acid accumulation into synaptic vesicles: purification and initial characterization. Proc. Natl. Acad. Sci. USA 94: 4137-4142.
58. Tamura, Y. et al 2001. IPF, a vesicular uptake inhibitory protein factor, can reduce the Ca(2+)-dependent, evoked release of glutamate, GABA and serotonin. J. Neurochem. 76: 1153-1164.
59. Snead, A.N. et al 2007. Thyronamines inhibit plasma membrane and vesicular monoamine transport. ACS Chem. Biol. 2: 390-398.
60. Brunk, I. et al 2006. The first luminal domain of vesicular monoamine transporters mediates G-protein-dependent regulation of transmitter uptake. J. Biol. Chem. 281: 33373-33385.
61. Brunk, I. et al 2009. Ca2+-dependent activator proteins of secretion promote vesicular monoamine uptake. J. Biol. Chem. 284: 1050-1056.
62. Brunk, I. et al 2008. Deletion of Go2alpha abolishes cocaine-induced behavioral sensitization by disturbing the striatal dopamine system. FASEB J. 22: 3736-3746.
63. Yao, J., J.D. Erickson & L.B. Hersh 2004. Protein kinase A affects trafficking of the vesicular monoamine transporters in PC12 cells. Traffic 5: 1006-1016.
64. Beckmann, J.S. et al 2010. The Novel Pyrrolidine nor-Lobelane Analog UKCP-110 (cis-2, 5-di-(2-Phenethyl)-pyrrolidine Hydrochloride) Inhibits VMAT2 Function, Methamphetamine-evoked Dopamine Release, and Methamphetamine Self-administration in Rats. J. Pharmacol. Exp. Ther.
65. Nickell, J.R. et al 2010. Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2. J. Pharmacol. Exp. Ther. 332: 612-621.
66. Montesinos, M.S. et al 2008. The crucial role of chromogranins in storage and exocytosis revealed using chromaffin cells from chromogranin A null mouse. J. Neurosci. 28: 3350-3358.
67. Venton, B.J. et al 2006. Cocaine increases dopamine release by mobilization of a synapsin-dependent reserve pool. J. Neurosci. 26: 3206-3209.
68. Pothos, E.N. et al. 2000. Synaptic vesicle transporter expression regulates vesicle phenotype and quantal size. J. Neurosci. 20: 7297-7306.
69. Fukushima, S. et al 2007. Methamphetamine-induced locomotor activity and sensitization in dopamine transporter and vesicular monoamine transporter 2 double mutant mice. Psychopharmacology (Berl). 193: 55-62.
70. Persico, A.M. et al 1995. Exclusion of close linkage between the synaptic vesicular monoamine transporter locus and schizophrenia spectrum disorders. Am. J. Med. Genet. 60: 563-565.
71. Hall, F.S., I. Sora & G.R. Uhl 2003. Sex-dependent modulation of ethanol consumption in vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) knockout mice. Neuropsychopharmacology 28: 620-628.
72. Savelieva, K.V., W.M. Caudle & G.W. Miller 2006. Altered ethanol-associated behaviors in vesicular monoamine transporter heterozygote knockout mice. Alcohol 40: 87-94.
73. Barr, G.A. et al 2009. Transitions in infant learning are modulated by dopamine in the amygdala. Nat Neurosci. 12: 1367-1369.
74. Fasano, A. & A.R. Bentivoglio 2009. Tetrabenazine. Expert Opin Pharmacother. 10: 2883-2896.
75. Jankovic, J. 2009. Treatment of hyperkinetic movement disorders. Lancet Neurol. 8: 844-856.
76. Thiriot, D.S., M.K. Sievert & A.E. Ruoho 2002. Identification of human vesicle monoamine transporter (VMAT2) lumenal cysteines that form an intramolecular disulfide bond. Biochemistry 41: 6346-6353.
77. Suzuki, M. et al 2001. Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers. Synapse 41: 329-336.
78. Bohnen, N.I. et al 2006. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J/Cereb. Blood Flow Metab. 26: 1198-1212.
79. de la Fuente-Fernandez, R. et al 2009. Visualizing vesicular dopamine dynamics in Parkinson's disease. Synapse 63: 713-716.
80. Boileau, I. et al 2008. Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: is VMAT2 a stable dopamine neuron biomarker J. Neurosci. 28: 9850-9856.
81. 11C]DTBZ study in humans. Synapse 64: 417-420.
82. 11C]dihydrotetrabenazine binding in rat striatum: sensitivity to dopamine concentrations. Nucl. Med. Biol. 37: 3-8.
83. Anlauf, M. et al 2004. The vesicular monoamine transporter 2 (VMAT2) is expressed by normal and tumor cutaneous mast cells and Langerhans cells of the skin but is absent from Langerhans cell histiocytosis. J. Histochem. Cytochem. 52: 779-788.
84. Weihe, E. et al 1998. VMAT2 is the transporter mediating sequestration of monoamines in rat and human platelets, mast cells, and cutaneous dendritic cells. Soc. Neurosci. Abstr. Nov. 7-12: #301.301.
85. Anlauf, M. et al 2006. Vesicular Monoamine Transporter 2 (VMAT2) Expression in Hematopoietic Cells and in Patients with Systemic Mastocytosis. J. Histochem. Cytochem. 54: 201-213.
86. Schmitt, K.C. & M.E. Reith 2010. Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse. Ann. N. Y. Acad. Sci. 1187: 316-340.
87. Naudon, L. et al 1996. Reserpine affects differentially the density of the vesicular monoamine transporter and dihydrotetrabenazine binding sites. Eur. J. Neurosci. 8: 842-846.
88. Wilson, J.M. & S.J. Kish 1996. The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J Neurosci. 16: 3507-3510.
89. Wilson, J.M. et al 1996. Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann. Neurol. 40: 428-439.
90. Wilson, J.M. et al 1996. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat. Med. 2: 699-703.
91. Schwartz, K. et al 2007. Cocaine, but not amphetamine, short term treatment elevates the density of rat brain vesicular monoamine transporter 2. J. Neural. Transm. 114: 427-430.
92. Li, H. et al 2005. Sorting of vesicular monoamine transporter 2 to the regulated secretory pathway confers the somatodendritic exocytosis of monoamines. Neuron 48: 619-633.